The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Targeting the tumor vasculature to enhance T cell activity
Open accessAbstract
T cells play a critical role in tumor immune surveillance as evidenced by extensive mouse-tumor model studies as well as encouraging patient responses to adoptive T cell therapies and dendritic cell vaccines. It is well established that the interplay of tumor cells with their local cellular environment can trigger events that are immunoinhibitory to T cells. More recently it is emerging that the tumor vasculature itself constitutes an important barrier to T cells. Endothelial cells lining the vessels can suppress T cell activity, target them for destruction, and block them from gaining entry into the tumor in the first place through the deregulation of adhesion molecules. Here we review approaches to break this tumor endothelial barrier and enhance T cell activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Immunosuppressive Strategies that are Mediated by Tumor Cells
Rabinovich, G. A., Gabrilovich, D., & Sotomayor, E. M. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141609 · Cited by 1,702
Adoptive immunotherapy for cancer: harnessing the T cell response
Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Gao, Q., Qiu, S.-J., Fan, J., Zhou, J., Wang, X.-Y., Xiao, Y.-S., Xu, Y., Li, Y.-W., & Tang, Z.-Y. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4565 · Cited by 1,110
Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
Motz, G. T., Santoro, S. P., Wang, L.-P., Garrabrant, T., Lastra, R. R., Hagemann, I. S., Lal, P., Feldman, M. D., Benencia, F., & Coukos, G. (2014) · Nature Medicine · doi:10.1038/nm.3541 · Cited by 1,035
Self-citationCytotoxic T lymphocytes: all roads lead to death
Barry, M., & Bleackley, R. C. (2002) · Nature Reviews Immunology · doi:10.1038/nri819 · Cited by 933
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
An inducible caspase 9 safety switch for T-cell therapy
Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Self-citationThe endothelin axis: emerging role in cancer
Nelson, J., Bagnato, A., Battistini, B., & Nisen, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc990 · Cited by 564
Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D., O'Brien-Jenkins, A., Gimotty, P. A., & Coukos, G. (2008) · Nature Medicine · doi:10.1038/nm1699 · Cited by 546
Self-citationThrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth
Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 540
Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies
Shih, T., & Lindley, C. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.11.015 · Cited by 521
Multiple roles for CD4+ T cells in anti‐tumor immune responses
Kennedy, R., & Celis, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00616.x · Cited by 511
The role of junctional adhesion molecules in vascular inflammation
Weber, C., Fraemohs, L., & Dejana, E. (2007) · Nature Reviews Immunology · doi:10.1038/nri2096 · Cited by 503
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
Finke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis
Rodig, N., Ryan, T., Allen, J. A., Pang, H., Grabie, N., Chernova, T., Greenfield, E. A., Liang, S. C., Sharpe, A. H., Lichtman, A. H., et al. (2003) · European Journal of Immunology · doi:10.1002/eji.200324270 · Cited by 492
A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
COBLEIGH, M. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.013 · Cited by 488
Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation
Ley, K., & Kansas, G. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1351 · Cited by 453
Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., & Corti, A. (2000) · Nature Biotechnology · doi:10.1038/81183 · Cited by 419
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth
Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., & Reisfeld, R. A. (2002) · Nature Medicine · doi:10.1038/nm1202-794 · Cited by 400
Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S., & Chen, L. (1998) · Cellular Immunology · doi:10.1006/cimm.1998.1396 · Cited by 363
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Endothelin 1 in cancer: biological implications and therapeutic opportunities
Rosanò, L., Spinella, F., & Bagnato, A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3546 · Cited by 348
Salani, D., Taraboletti, G., Rosanò, L., Di Castro, V., Borsotti, P., Giavazzi, R., & Bagnato, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64807-9 · Cited by 341
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Self-citationB7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis
Mazanet, M. M., & Hughes, C. C. W. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3581 · Cited by 326
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Osada, T., Chong, G., Tansik, R., Hong, T., Spector, N., Kumar, R., Hurwitz, H. I., Dev, I., Nixon, A. B., Lyerly, H. K., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0441-x · Cited by 311
Chapuis, A. G., Ragnarsson, G. B., Nguyen, H. N., Chaney, C. N., Pufnock, J. S., Schmitt, T. M., Duerkopp, N., Roberts, I. M., Pogosov, G. L., Ho, W. Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004916 · Cited by 311
Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S., et al. (2011) · Blood · doi:10.1182/blood-2010-05-286286 · Cited by 307
Krambeck, A. E., Thompson, R. H., Dong, H., Lohse, C. M., Park, E. S., Kuntz, S. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600937103 · Cited by 305
Griffioen, A. W., Damen, C. A., Martinotti, S., Blijham, G. H., & Groenewegen, G. (1996) · PubMed · Cited by 282
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4038 · Cited by 266
Self-citationChinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time
Aleksic, M., Dushek, O., Zhang, H., Shenderov, E., Chen, J.-L., Cerundolo, V., Coombs, D., & van der Merwe, P. A. (2010) · Immunity · doi:10.1016/j.immuni.2009.11.013 · Cited by 249
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
Zang, X., Sullivan, P. S., Soslow, R. A., Waitz, R., Reuter, V. E., Wilton, A., Thaler, H. T., Arul, M., Slovin, S. F., Wei, J., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.95 · Cited by 249
Zhong, S., Malecek, K., Johnson, L. A., Yu, Z., Vega-Saenz de Miera, E., Darvishian, F., McGary, K., Huang, K., Boyer, J., Corse, E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221609110 · Cited by 245
Dikov, M. M., Ohm, J. E., Ray, N., Tchekneva, E. E., Burlison, J., Moghanaki, D., Nadaf, S., & Carbone, D. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.215 · Cited by 244
Rettig, W. J., Garin-Chesa, P., Healey, J. H., Su, S. L., Jaffe, E. A., & Old, L. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10832 · Cited by 242
Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine
Wei, Y.-Q., Wang, Q.-R., Zhao, X., Yang, L., Tian, L., Lu, Y., Kang, B., Lu, C.-J., Huang, M.-J., Lou, Y.-Y., et al. (2000) · Nature Medicine · doi:10.1038/80506 · Cited by 233
Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration
Curnis, F., Sacchi, A., & Corti, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215223 · Cited by 228
Chiang, C. L.-L., Kandalaft, L. E., Tanyi, J., Hagemann, A. R., Motz, G. T., Svoronos, N., Montone, K., Mantia-Smaldone, G. M., Smith, L., Nisenbaum, H. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1185 · Cited by 218
Self-citationSata, M., & Walsh, K. (1998) · Nature Medicine · doi:10.1038/nm0498-415 · Cited by 215
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Vessel abnormalization: another hallmark of cancer?
De Bock, K., Cauwenberghs, S., & Carmeliet, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.008 · Cited by 213
Adotevi, O., Pere, H., Ravel, P., Haicheur, N., Badoual, C., Merillon, N., Medioni, J., Peyrard, S., Roncelin, S., Verkarre, V., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f4c208 · Cited by 213
Palladino, M. A., Shalaby, M. R., Kramer, S. M., Ferraiolo, B. L., Baughman, R. A., Deleo, A. B., Crase, D., Marafino, B., Aggarwal, B. B., Figari, I. S., et al. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.11.4023 · Cited by 201
Spinella, F., Rosanò, L., Di Castro, V., Natali, P. G., & Bagnato, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202421200 · Cited by 199
Tumor Vascular Proteins As Biomarkers in Ovarian Cancer
Buckanovich, R. J., Sasaroli, D., O'Brien-Jenkins, A., Botbyl, J., Hammond, R., Katsaros, D., Sandaltzopoulos, R., Liotta, L. A., Gimotty, P. A., & Coukos, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8583 · Cited by 195
Self-citationMacFadyen, J. R., Haworth, O., Roberston, D., Hardie, D., Webster, M.-T., Morris, H. R., Panico, M., Sutton-Smith, M., Dell, A., van der Geer, P., et al. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.03.071 · Cited by 182
Shetty, S., Weston, C. J., Oo, Y. H., Westerlund, N., Stamataki, Z., Youster, J., Hubscher, S. G., Salmi, M., Jalkanen, S., Lalor, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002961 · Cited by 173
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Johansson, A., Hamzah, J., Payne, C. J., & Ganss, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118296109 · Cited by 172
Riesenberg, R., Weiler, C., Spring, O., Eder, M., Buchner, A., Popp, T., Castro, M., Kammerer, R., Takikawa, O., Hatz, R. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0942 · Cited by 170
Kandalaft, L. E., Powell, Jr., Chiang, C. L., Tanyi, J., Kim, S., Bosch, M., Montone, K., Mick, R., Levine, B. L., Torigian, D. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.22664 · Cited by 159
Self-citationCalcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., Corti, A., & Bellone, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101877 · Cited by 153
Li, Y., Wang, M.-N., Li, H., King, K. D., Bassi, R., Sun, H., Santiago, A., Hooper, A. T., Böhlen, P., & Hicklin, D. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020072 · Cited by 153
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
Gajewski, T. F., Fuertes, M. B., Spaapen, R. M., Zheng, Y., & Kline, J. P. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.11.013 · Cited by 145
Sacchi, A., Gasparri, A. M., Gallo‐Stampino, C., Toma, S., Curnis, F., & Corti, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1147 · Cited by 144
Palazón, A., Teijeira, Á., Martínez‐Forero, I., Hervás‐Stubbs, S., Roncal, C., Peñuelas, I., Dubrot, J., Morales‐Kastresana, A., Perez‐Gracia, J. L., Ochoa, M. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1733 · Cited by 143
Endothelium-derived factors as paracrine mediators of prostate cancer progression
Pirtskhalaishvili, G., & Nelson, J. B. (2000) · The Prostate · Cited by 142
Irving, M. B., Zoete, V., Hebeisen, M., Schmid, D. A., Baumgärtner, P., Guillaume, P., Romero, P. J., Speiser, D. E., Luescher, I. F., Rufer, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357673 · Cited by 128
Self-citationHuman endothelial cells generate Th17 and regulatory T cells under inflammatory conditions
Taflin, C., Favier, B., Baudhuin, J., Savenay, A., Hémon, P., Bensussan, A., Charron, D. J., Glotz, D., & Mooney, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011811108 · Cited by 118
Two Steps Forward in the Treatment of Colorectal Cancer
Mayer, R. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048098 · Cited by 116
Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma
Simonavicius, N., Robertson, D. M., Bax, D. A., Jones, C., Huijbers, I. J., & Isacke, C. M. (2008) · Modern Pathology · doi:10.1038/modpathol.3801006 · Cited by 115
Wei, Y.-Q., Huang, M.-J., Li, Y., Zhao, X., Tian, L., Lü, Y., Shu, J.-M., Lu, C.-J., Niu, T., Kang, B., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191112198 · Cited by 113
Chinnasamy, D., Tran, E., Yu, Z., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3913 · Cited by 113
Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure‐Kunkel, M., Teitz‐Tennenbaum, S., & Chang, A. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0590 · Cited by 111
A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Dayan, F., Mazure, N. M., Brahimi-Horn, M. C., & Pouysségur, J. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0006-3 · Cited by 109
Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M., & Chen, L. (2003) · Blood · doi:10.1182/blood-2003-06-2184 · Cited by 108
CD137 Expression in Tumor Vessel Walls
Broll, K., Richter, G., Pauly, S., Hofstaedter, F., & Schwarz, H. (2001) · American Journal of Clinical Pathology · doi:10.1309/e343-kmyx-w3y2-10ky · Cited by 103
Santoro, S. P., Kim, S., Motz, G. T., Alatzoglou, D., Li, C., Irving, M. B., Powell, D. J., & Coukos, G. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0192 · Cited by 102
Self-citationWang, W., Ma, Y., Li, J., Shi, H., Lq, W., Guo, F.-C., Zhang, J., Li, D., Mo, B.-H., Wen, F., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.19 · Cited by 97
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery
Bouzin, C., & Féron, O. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.001 · Cited by 95
Kraan, J., van den Broek, P., Verhoef, C. K., Grünhagen, D. J., Taal, W., Gratama, J. W., & Sleijfer, S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.286 · Cited by 89
Cham, K. K., Baker, J. H. E., Takhar, K. S., Flexman, J. A., Wong, M. Q., Owen, D. A., Yung, A. C., Kozłowski, P., Reinsberg, S. A., Chu, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605727 · Cited by 87
Role of cell adhesion molecules in leukocyte recruitment in the liver and gut
Ala, A., Dhillon, A. P., & Hodgson, H. J. F. (2003) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2003.00235.x · Cited by 79
Tumor endothelial marker 1–specific DNA vaccination targets tumor vasculature
Facciponte, J. G., Ugel, S., Sanctis, F. D., Li, C., Wang, L., Nair, G. P., Sehgal, S., Raj, A., Matthaiou, E. I., Coukos, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67382 · Cited by 78
Self-citationIntratumoral T Cell Subset Ratios and Fas Ligand Expression on Brain Tumor Endothelium
Yu, J. S., Lee, P. K., Ehtesham, M., Samoto, K., Black, K. L., & Wheeler, C. J. (2003) · Journal of Neuro-Oncology · doi:10.1007/bf02700020 · Cited by 73
Murine Endothelial Cell Lines as Models of Tumor Endothelial Cells
Walter-Yohrling, J., Morgenbesser, S. D., Rouleau, C., Bagley, R. G., Callahan, M., Weber, W. D., & Teicher, B. A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1013 · Cited by 68
Blaschitz, A., Gauster, M., Fuchs, D., Lang, I., Maschke, P., Ulrich, D., Karpf, E., Takikawa, O., Schimek, M. G., Dohr, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021774 · Cited by 67
Okaji, Y., Tsuno, N. H., Kitayama, J., Saito, S., Takahashi, T., Kawai, K., Yazawa, K., Asakage, M., Hori, N., Watanabe, T., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03175.x · Cited by 60
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248
Bagley, R. G., Rouleau, C., Martin, T. S., Boutin, P., Weber, W. D., Ruzek, M. C., Honma, N., Nacht, M., Shankara, S., Kataoka, S., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0050 · Cited by 51
Tumors induce the formation of suppressor endothelial cells in vivo
Mulligan, J. K., & Young, M. R. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0747-y · Cited by 49
Tumor necrosis factor‐mediated interactions between inflammatory response and tumor vascular bed
ten Hagen, T. L. M., Seynhaeve, A. L. B., & Eggermont, A. M. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00619.x · Cited by 40
Zuo, S., Chen, Y., Wu, Z. P., Liu, X., Liu, C., Zhou, Y. C., Wu, C. L., Jin, C. G., Gu, Y. L., Li, J., et al. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.174 · Cited by 38
Miller, D. W., Vosseler, S., Mirancea, N., Hicklin, D. J., Böhlen, P., Völcker, H. E., Holz, F. G., & Fusenig, N. E. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61226-6 · Cited by 37
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer
Bellone, M., Mondino, A., & Corti, A. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.02.003 · Cited by 37
Rajeshkumar, N. V., Rai, A., & Gulati, A. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9000-3 · Cited by 34
Casós, K., Siguero, L., Fernández‐Figueras, M. T., León, X., Sardá, M.-P., Vila, L., & Camacho, M. (2011) · Microvascular Research · doi:10.1016/j.mvr.2011.01.006 · Cited by 30
Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine β-Defensin 2 and mFlk-1
Wang, Y., Wang, G., Wen, Y., Wang, L. Y., Chen, X., Chen, P., Kan, B., Li, J., Huang, C., Lü, Y., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1587 · Cited by 30
Luo, Y., Markowitz, D., Xiang, R., Zhou, H., & Reisfeld, R. A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.043 · Cited by 20
The Puzzling Role of TRAIL in Endothelial Cell Biology
Secchiero, P., & Zauli, G. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.158451 · Cited by 15
Cited by
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,411
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Metadata
- Authors
- Lanitis, E., Irving, M., & Coukos, G.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 33
- Pages
- 55-63
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2071456955
- Cited by
- 338
- References
- 136
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.